Objectives This study aimed to compare the performance of the CURB-65, A-DROP, and NEWS scores for the prediction of clinical outcomes in patients with community-acquired pneumonia (CAP) in a Colombian population. Materials and Methods In this retrospective cohort study, we analyzed data from patients with CAP seen within the emergency department, general ward hospitalization, and intensive care unit in a tertiary care health institution located in Cundinamarca, from January 2012 to December 2020. Results A total of 1651 patients were included in our study. CURB-65 and A-DROP scores showed a good performance for primary outcomes related to in-hospital mortality and 30-day mortality with an area under the receiver operating characteristic curve (AUC-ROC) of 0.72 (95% confidence interval [CI], 0.69–0.76) and 0.69 (95% CI, 0.65–0.73), respectively. On the other hand, NEWS score exhibited an acceptable performance in predicting in-hospital mortality and 30-day mortality; furthermore, it showed better performance in anticipating the need for invasive mechanical ventilation and vasopressor therapy (AUC-ROC of 0.64 [95% CI, 0.59–0.69] and AUC-ROC of 0.65 [95% CI, 0.60–0.69], respectively). Conclusions Our findings suggest that, in patients with CAP, the use of CURB-65, A-DROP, and NEWS scores helps the clinician to predict in-hospital and 30-day mortality. However, NEWS score proves to be a more convenient tool to predict the need for several life support measures and management in the intensive care unit.

Introducción. Se han descrito múltiples efectos adversos con el uso de la terapia biológica para enfermedades autoinmunitarias, muchos de ellos secundarios al estado de inmunosupresión, como las infecciones bacterianas, fúngicas o virales.Caso clínico. Se presenta el caso de una mujer de 64 años con diagnóstico comprobado de criptococosis diseminada secundaria al uso de tofacitinib. Se descartaron otras causas de inmunosupresión, como infección por el virus de la inmunodeficiencia humana (HIV). Tres años antes se le había diagnosticado artritis reumatoide y se encontraba en tratamiento farmacológico con un agente biológico que inhibe las enzimas JAK. Se han descrito muy pocos casos de criptococosis pulmonar y meníngea en este tipo de pacientes. Conclusión. Este reporte de caso es útil para que otros médicos tratantes tengan presente la posibilidad de este tipo de infección fúngica invasora asociada con la terapia biológica y el enfoque de gestión de riesgo.